Baidu
map

Ophthalmology:青少年T1 DM或T2DM患者糖尿病视网膜病变的风险几何?

2017-04-26 贾朝娟 环球医学

儿童和青少年2型糖尿病(T2DM)的发病率在不断增加。2017年4月,发表在《Ophthalmology》的一项研究调查了青年糖尿病患者糖尿病视网膜病变(DR)的风险因素,并比较了1型糖尿病(T1DM)与T2DM的DR率。

儿童和青少年2型糖尿病(T2DM)的发病率在不断增加。2017年4月,发表在《Ophthalmology》的一项研究调查了青年糖尿病患者糖尿病视网膜病变(DR)的风险因素,并比较了1型糖尿病(T1DM)与T2DM的DR率。

目的:尽管2型糖尿病(T2DM)在儿童和青少年中的流行率不断增加,但有关其进展为糖尿病视网膜病变(DR)的风险知之甚少。研究者试图识别青年糖尿病患者DR的风险因素,比较1型糖尿病(T1DM)和T2DM的DR率,并评估依从美国眼科协会、美国儿科协会和美国糖尿病协会提出的DR筛选指南能否全部查出青年DR。

设计:回顾性观察性纵向队列研究。

受试者:在大型US管理的护理网络中纳入的年龄≤21岁的新诊断为T1DM或T2DM的青少年。

方法:在这项研究中,对年龄≤21岁的新诊断为T1DM或T2DM的青少年进行眼科监测,研究者识别出DR发病率和时间。用Kaplan–Meier生存曲线评估受试者首次诊断为DR的时间。多变量Cox比例危险回归模型识别出进展至DR危险相关的因素。模型预测最初糖尿病诊断的日历年、性别、民族/种族,净值和糖化血红蛋白A1c分数(HbA1c)。

主要结局测试指标:进展至DR的危险比(HRs)及95%置信区间(CIs)。

结果:在2240名T1DM和1768名T2DM青少年中,中位随访3.2和3.1年后,分别有20.1%和7.2%进展为DR,生存曲线显示T1DM青少年进展至DR快于T2DM(P<0.0001)。HbA1c每增加1个点,T1DM和T2DM青少年的DR危险分别增加20%(HR = 1.20;95% CI 1.06~1.35)和30%(HR = 1.30;95% CI 1.08~1.56)。目前指南显示,在我们研究中,最初糖尿病诊断后3~5年的眼科筛查中,>18%的T1DM青少年已经接受≥1次的DR诊断。

结论:T1DM或T2DM青少年显示出相当大的糖尿病视网膜病变风险,并且应该接受眼科护理专业的常规筛查,以确保及时的DR诊断,并限制进展至威胁视力的疾病。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717732, encodeId=d7571e17732cf, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Thu Dec 28 10:14:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269867, encodeId=f227126986e22, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413880, encodeId=dc5b1413880f1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541190, encodeId=8e2d15411901d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190861, encodeId=debd19086165, content=不错,又学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Wed Apr 26 22:04:19 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1717732, encodeId=d7571e17732cf, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Thu Dec 28 10:14:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269867, encodeId=f227126986e22, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413880, encodeId=dc5b1413880f1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541190, encodeId=8e2d15411901d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190861, encodeId=debd19086165, content=不错,又学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Wed Apr 26 22:04:19 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
    2017-04-28 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1717732, encodeId=d7571e17732cf, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Thu Dec 28 10:14:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269867, encodeId=f227126986e22, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413880, encodeId=dc5b1413880f1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541190, encodeId=8e2d15411901d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190861, encodeId=debd19086165, content=不错,又学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Wed Apr 26 22:04:19 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1717732, encodeId=d7571e17732cf, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Thu Dec 28 10:14:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269867, encodeId=f227126986e22, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413880, encodeId=dc5b1413880f1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541190, encodeId=8e2d15411901d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190861, encodeId=debd19086165, content=不错,又学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Wed Apr 26 22:04:19 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1717732, encodeId=d7571e17732cf, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Thu Dec 28 10:14:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269867, encodeId=f227126986e22, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413880, encodeId=dc5b1413880f1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541190, encodeId=8e2d15411901d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 28 08:14:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190861, encodeId=debd19086165, content=不错,又学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Wed Apr 26 22:04:19 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
    2017-04-26 林3301

    不错,又学习了

    0

相关资讯

Faseb J:维生素A会造成肥胖和糖尿病?

【维生素A+高脂饮食=肥胖和糖尿病风险增加】维生素A是人体维持正常运作需要的重要营养物质。但是今天在芝加哥的“实验生物学2017”实验生物学年会上提出的新研究表明,高脂肪饮食中正常水平的维生素A可能会对与葡萄糖和脂肪代谢相关的肝脏基因的表达产生负面影响。研究人员给两组老鼠喂食高脂肪饮食8周。一组消耗正常量的维生素A(“足够”),而另一组则食用缺乏该营养物质(“缺乏”)的食物。研究小组每周测量大鼠体

J Hypertens:没有糖尿病的人吃二甲双胍也可降低血压,空腹血糖受损者可降低5 mmHg

二甲双胍是治疗2型糖尿病的老药了,虽老但很传奇,之前还有研究发现其具有降脂、减肥、抗癌作用,而近期阜外医院周龙、赵连成等进行的一项Meta分析还显示,二甲双胍还可降低非糖尿病者的收缩压水平,尤其是肥胖或糖尿病前期者。研究显示,二甲双胍可平均降低非糖尿病患者收缩压2 mmHg。其亚组分析显示,对空腹血糖受损患者和体重指数≥30 kg/m2肥胖者降压效应尤其显著,分别可平均降低5.03 mmHg和3

Lancet:这个药可帮助肥胖和糖尿病前期个体降低糖尿病风险

2017年4月,发表在《Lancet》的一项由英国、丹麦、美国等科学家进行的随机双盲试验,比较了糖尿病前期个体使用3年的利拉鲁肽和安慰剂对2型糖尿病风险降低和体重管理的效果。

Chest:结核病合并糖尿病的流行病学和临床管理

目前,研究者们对2型糖尿病(DM)和结核病(TB)之间的相互作用越来越感兴趣,但许多研究问题仍然没有得到解决。流行病学家、基础科学家和临床专家最近召集并确定了优先事项。近期,有关流行病学、临床管理和公共卫生优先研究领域的相关认识发表在杂志Chest上。首先,从流行病学的角度来看,需要更多的研究来确定结核病患者发生暂时性高血糖的重要性,以及DM对全球多药耐药(MDR)-TB流行的重要性。第二,关于合

Chest:结核病合并糖尿病的基础生物学机制

很多研究者对2型糖尿病(DM)和结核病(TB)之间的相互作用越来越感兴趣,尽管两者之间潜在的生物学机制可能对临床的治疗和管理产生一定的影响,但是,目前相关知识知之甚少。近期,Chest杂志上发表了流行病学、公共卫生、基础科学和临床研究专家召集并确定的研究重点,以阐明TB和DM共同发生的潜在机制。目前关于在结核病患者中出现DM后,患者免疫力变化的相关研究差异很大,大多数研究表明患者的先天性免疫力不佳

关于HbA1c,不得不说的五件事!

糖化血红蛋白能反映糖尿病患者过去2~3个月内的平均血糖水平,而且不受抽血时间、是否空腹、是否使用降糖药物等因素的影响。但是关于这项指标不少患者存在一定的误区,本文总结了相关内容,帮您一步到位向患者说个明白! 误区一  数值越接近正常越好 不少患者认为糖化血红蛋白越接近正常值越好(标准检测方法的正常值范围为4%~5.9%),这种认识是不完善的。糖尿病治疗强调个体化原

Baidu
map
Baidu
map
Baidu
map